Sulis Therapeutics ApS
Private limited companyCVR 44445832København NActive
Sulis Therapeutics ApS is a private limited company, based in København N, active in research and experimental development on natural sciences and engineering, founded in 2023. Equity was negative at the end of 2025 (−DKK 939k). The company made a loss in both 2024 and 2025, most recently DKK 893k. 8 other companies in the database are registered at the same address.
Key figures · financial year 2025
What has changed
calculated from recorded figures and datesFinancials: 2025 against 2024
- The loss grew: from DKK 202k to DKK 893k (2024 → 2025).
Management and owners, last 24 months
- New in management: Martin Roelsgaard Jakobsen (board member, 05/08/2025), Claus Elsborg Olesen (board member, 01/06/2026) and Sten Verland (chair of the board, 01/06/2026) (+1).
- Stepped down: Claus Elsborg Olesen (chair of the board, 31/05/2026).
Registrations, last 24 months
- 01/01/2025: Industry changed to Research and experimental development on natural sciences and engineering (721000)
Calculated from the latest two annual reports in sequence and from registrations in CVR. A figure that is missing in either year gives no line, and we derive no figures.
Financial statements
Financial years 2023–2025 · amounts in DKK thousandEquity and net profit
| 2023 | 2024 | 2025 | Change | |
|---|---|---|---|---|
| Revenue | not stated | not stated | not stated | – |
| Gross profit | −2 | −167 | −866 | −418.2% |
| Operating profit (EBIT) | – | −225 | −994 | −341.1% |
| Profit before tax | −5 | −236 | −1,047 | −343.5% |
| Net profit | −5 | −202 | −893 | −341.2% |
| Total assets | 196 | 533 | 1,505 | +182.1% |
| Equity | 156 | −46 | −939 | −1,947.5% |
| Liabilities | 40 | 579 | 2,443 | +321.8% |
| Cash and cash equivalents | 9 | 367 | 1,184 | +222.5% |
| Average number of employees | – | 1 | 1 | 0% |
Source: annual reports filed with the Danish Business Authority (XBRL). Figures for the company (not the group); change is the latest year against the year before. “–” means the figure is not stated in the annual report. Revenue is not stated for 2023, 2024, 2025: smaller companies may omit it, and we do not derive it from other figures.
Download the figures as CSV · free with an account, amounts in whole DKK
Signals from the financial statements
calculated from the 2025 figuresNegative equity
Equity was −DKK 939k at the end of 2025.
How is this calculated?
Equity in the latest annual report is below zero.
Loss for 3 years in a row
Net result has been negative in 2023–2025.
How is this calculated?
Net result is negative in the two or more latest annual reports in a row.
The signals are rules applied to the figures in the annual reports. They are not an assessment or credit rating of the company. See Data and method.
Annual reports
3 financial years| Financial year | Period | Published | Figures for | Documents |
|---|---|---|---|---|
| 2025 | 01/01/2025 – 31/12/2025 | 02/06/2026 | The company | PDF not statedXBRL |
| 2024 | 01/01/2024 – 31/12/2024 | 27/05/2025 | The company | PDFXBRL |
| 2023 | 21/11/2023 – 31/12/2023 | 08/05/2024 | The company | PDFXBRL |
The figures from all the annual reports are shown on this page. The documents themselves (PDF and XBRL, the machine-readable edition) are downloaded with a Pro account: sign in or create a free account, and then choose Pro. XBRL is the edition the figures on the page are read from.
Employees
monthly figures from CVRPosition in the industry
431 companies in the databaseComparison with the other companies in research and experimental development on natural sciences and engineering based on the latest financial year.
Industry median: gross profit DKK 616k, net profit −DKK 892k, equity DKK 2m, 5 employees.
Compared with similar companies
size, age and company form| Group | Gross profit | Equity |
|---|---|---|
| Companies with fewer than 20 employees69,967 companies in the comparison | No. 68,660of 69,742 Better than 2% | No. 67,039of 69,964 Better than 4% |
| Same industry and fewer than 20 employees329 companies in the comparison | No. 244of 323 Better than 25% | No. 248of 329 Better than 25% |
| Companies that are founded within the last five years16,662 companies in the comparison | No. 16,264of 16,614 Better than 2% | No. 15,829of 16,661 Better than 5% |
| All companies of type ApS66,508 companies in the comparison | No. 65,541of 66,379 Better than 1% | No. 63,554of 66,505 Better than 4% |
The rank is calculated among companies in the database with a figure for the latest financial year, and is shown only for groups of at least ten companies.
Compare with the industry
Research and experimental development on natural sciences and engineering- Sulis Therapeutics ApS−DKK 866k
- Carlsberg A/SDKK 40.2bn
- Zealand Pharma A/SDKK 9.2bn
- Sulis Therapeutics ApS−DKK 893k
- Carlsberg A/SDKK 7bn
- Zealand Pharma A/SDKK 6.5bn
- Sulis Therapeutics ApS−DKK 939k
- Carlsberg A/SDKK 30.7bn
- Zealand Pharma A/SDKK 14.8bn
- Sulis Therapeutics ApS2
- Carlsberg A/S107
- Zealand Pharma A/S569
Latest financial year per company. Choose up to three companies from the largest in the industry.
Owners and group
from the Public Ownership Register- Claus Olesen Holding ApS50%
- MR Jakobsen Holding ApS15%
- Shinka Life Sciences AB25%
Management
4 active registrationsExecutive management
| Name | Role | Appointed |
|---|---|---|
| Claus Elsborg Olesen | Director | 21/11/2023 |
Board of directors
| Name | Role | Appointed |
|---|---|---|
| Martin Roelsgaard Jakobsen | Board member | 05/08/2025 |
| Claus Elsborg Olesen | Board member | 01/06/2026 |
| Sten Verland | Chair of the board | 01/06/2026 |
- Founders
- STIPE Therapeutics ApS
Former management (7)
| Name | Role | Appointed | Resigned |
|---|---|---|---|
| Sten Verland | Board member | 21/11/2023 | 27/06/2024 |
| Morten Døssing | Board member | 21/11/2023 | 27/06/2024 |
| Martin Roelsgaard Jakobsen | Board member | 21/11/2023 | 27/06/2024 |
| Regina Hodits | Board member | 21/11/2023 | 27/06/2024 |
| Christian Schetter | Chair of the board | 21/11/2023 | 27/06/2024 |
| Natalie Rose Sacks | Board member | 21/11/2023 | 31/12/2023 |
| Claus Elsborg Olesen | Chair of the board | 05/08/2025 | 31/05/2026 |
Signing rule: Selskabet tegnes af bestyrelsesformanden i forening med et bestyrelsesmedlem, eller af den samlede bestyrelse.
Address and production units
1 active production unitsOle Maaløes Vej 3
2200 København N
København Municipality · Postcode 2200
Other companies at the address (8)
- BII Holdings A/SOther financial service activities n.e.c.
- Skape Bio ApSResearch and experimental development on natural sciences and engineering
- Agrobiomics ApSResearch and experimental development on natural sciences and engineering
- Tetrakit Technologies ApSResearch and experimental development on natural sciences and engineering
- BioColor ApSResearch and experimental development on natural sciences and engineering
| Production unit | Address | Employees | P number |
|---|---|---|---|
| Sulis Therapeutics ApS | Ole Maaløes Vej 3, 2200 København N | 2 | 1029851774 |
Purpose
Selskabets formål er udvikling og kommercialisering af lægemidler og hermed forbundet virksomhed.
The purpose is quoted from the register in Danish.
Changes year by year
43 registered events20264 changesaccounts 1 · management 3
- AccountsAnnual report for 2025 published
- ManagementClaus Elsborg Olesen appointed board member
- ManagementSten Verland appointed chair of the board
- ManagementClaus Elsborg Olesen stepped down as chair of the board
20254 changesmanagement 2 · accounts 1 · industry 1
- ManagementClaus Elsborg Olesen appointed chair of the board
- ManagementMartin Roelsgaard Jakobsen appointed board member
- AccountsAnnual report for 2024 published
- IndustryIndustry changed to Research and experimental development on natural sciences and engineering (721000)
202419 changesaddress 3 · industry 1 · name 1 · management 5 · ownership 8 · accounts 1
- AddressMoved to Ole Maaløes Vej 3, 2200 København N
- AddressMoved to Ole Maaløes Vej 3, 2200 København N
- IndustryIndustry changed to Forskning og eksperimentel udvikling indenfor bioteknologi (721100)
- NameName changed from Selskabet af 21. november 2023 ApS to Sulis Therapeutics ApS
- ManagementChristian Schetter stepped down as chair of the board
- ManagementSten Verland stepped down as board member
- ManagementMorten Døssing stepped down as board member
- ManagementMartin Roelsgaard Jakobsen stepped down as board member
- ManagementRegina Hodits stepped down as board member
- OwnershipShinka Life Sciences AB registered as owner (25%)
- OwnershipCLAUS OLESEN HOLDING ApS registered as owner (50%)
- OwnershipMR Jakobsen Holding ApS registered as owner (15%)
- OwnershipSunstone Life Science Ventures Fund IV K/S is no longer registered as owner
- OwnershipWellington Partners Life Sciences V GmbH & Co. KG is no longer registered as owner
- OwnershipNovo Holdings A/S is no longer registered as owner
- OwnershipMR Jakobsen Holding ApS is no longer registered as owner
- OwnershipCLAUS OLESEN HOLDING ApS is no longer registered as owner
- AccountsAnnual report for 2023 published
- AddressMoved to Inge Lehmanns Gade 10, 8000 Aarhus C
202316 changesmanagement 8 · ownership 7 · founded 1
- ManagementNatalie Rose Sacks stepped down as board member
- OwnershipSunstone Life Science Ventures Fund IV K/S registered as owner (20%)
- OwnershipWellington Partners Life Sciences V GmbH & Co. KG registered as owner (20%)
- OwnershipMR Jakobsen Holding ApS registered as owner (10%)
- OwnershipNovo Holdings A/S registered as owner (20%)
- OwnershipCLAUS OLESEN HOLDING ApS registered as owner (10%)
- OwnershipSTIPE Therapeutics ApS is no longer registered as owner
- FoundedRegistered as Selskabet af 21. november 2023 ApS
- ManagementChristian Schetter appointed chair of the board
- ManagementSten Verland appointed board member
- ManagementClaus Elsborg Olesen appointed director
- ManagementNatalie Rose Sacks appointed board member
- ManagementMorten Døssing appointed board member
- ManagementMartin Roelsgaard Jakobsen appointed board member
- ManagementRegina Hodits appointed board member
- OwnershipSTIPE Therapeutics ApS registered as owner (100%)
Related companies
Same industry in København
- Genmab A/S676 employees
- 3shape A/S518 employees
- Carlsberg A/S107 employees
- IQVIA RDS Denmark A/S100 employees
- Nuevolution A/S100 employees
- Sunshine Enterprise Holding A/S73 employees
Same people in management
- Taconic Biosciences A/Svia Sten Verland
- NMD Pharma A/Svia Claus Elsborg Olesen
- Glycom A/Svia Sten Verland
- Scanbur A/Svia Sten Verland
- Orbis Medicines ApSvia Morten Døssing
- Minervax ApSvia Sten Verland
Largest in the industry
- Carlsberg A/SDKK 40.2bn
- Zealand Pharma A/SDKK 9.2bn
- Gubra A/SDKK 2.6bn
- Vestas Wind Systems A/SDKK 2.5bn
- Bang & Olufsen A/SDKK 1.4bn
- 3shape A/SDKK 1.3bn
Source and updates
The information comes from the Danish Central Business Register (Danish Business Authority) and from annual reports filed with the Danish Business Authority. Last synchronised 24/10/2026. The company is protected against advertising; contact details are not shown, and the data must not be used for marketing.